To focus on dengue vaccine, pneumonia solutions: Serum Institute

Vaccine manufacturer Serum Institute of Technology aims to triple its revenues to Rs 10,000 crore over the next three-four years, said CEO & ED, Adar Poonawalla.

The company is focusing on vaccinations for dengue and pneumonia solutions and sending them to Asian & African countries. Some of these will also go into regulated markets like the US and Europe in coming three-four years, said Poonawalla in an interview to CNBC-TV18.

When asked about the company’s plan to raise money by shedding 10-20 percent company stake, he said that the decision was to raise money for an acquisition but since that hasn’t come through they have put off that plan.

He also clarified that there are no merger plans with Cipla as such, but they do have marketing tie-ups with the company.